<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">In December 2019, multiple severe pneumonia cases emerged in Wuhan, Hubei, China
 <sup>
  <xref ref-type="bibr" rid="CR1">1</xref>
 </sup>. The causative agent was identified as a novel coronavirus, which was scientifically named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) called the disease caused by this virus as coronavirus disease 19 or COVID-19. With the vast and rapid spreading, the virus became pandemic in a short period, causing a severe outbreak in 218 countries and territories around the world. As of October, 2020, the number of confirmed cases of COVID-19 climbed above 42 million, with more than one million deaths globally
 <sup>
  <xref ref-type="bibr" rid="CR2">2</xref>
 </sup>. This catastrophic situation highlighted the urgent need of the entire population for the effective and affordable antiviral therapeutics to fight against the dreadful disease. 
</p>
